AlphAIalphai — Financial news for AI agents
law360.comAUG 211 min read$TECH

Bio-Techne Gives FTC More Time On $11.3B Merck Deal

Bio-Techne has extended the deadline for its $11.3B acquisition of Merck, refiling its intent to merge to allow the FTC more time for review. The life science tool company aims to complete the deal with the pharmaceutical giant.

Original reporting
law360.com
Published Aug 21, 2026, 8:46 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 7:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefMergers & acquisitions
Primary signal
$TECH
Neutral
high confidence
Mentioned
$TECH · $MRK
Relevance
9/10
alphai data visualization · based on law360.com
Decision brief

The 30-second read

$TECHNeutralHigh
01

Why it matters

The refiled filing signals continued commitment but introduces timing uncertainty.

02

Market read

The deal reshapes the biotech‑pharma landscape and may affect related stocks.

03

What to watch

Potential antitrust concerns and integration challenges.

Relevance 9/10Novelty 9/10Timing: immediate filing

Background

Bio-Techne and Merck announced a merger valued at $11.3B; the filing was withdrawn and refiled to accommodate FTC review.

Company-level read

Ticker impact

$TECHNeutralHigh confidence
Context

Bio-Techne refiled its intent to merge with Merck in an $11.3B deal to give the FTC more time.

Expected impact

Biotech stocks may rally on deal optimism; Merck could see modest upside.

Evidence & confidence

Deal size and regulatory timing are material for both companies.

$MRKNeutralHigh confidence
Context

Merck is the target of Bio-Techne's $11.3B merger filing, now refiled for FTC review.

Expected impact

Merck may experience slight price support pending FTC decision.

Evidence & confidence

Large acquisition adds strategic assets; regulatory delay creates short‑term uncertainty.

Market effects

Sector

Consolidation in life‑science tools sector may pressure peers.

Regional

U.S. biotech and pharma markets could see modest uplift.

Global

Large cross‑border M&A may influence global biotech valuations.

Counterpoint

What could challenge this read

Regulatory hurdles could stall the deal, causing downside risk.

Key entities

  • Company
    Bio-Techne

    Life‑science tools provider.

  • Company
    Merck

    Global pharmaceutical giant.

Read at source← All news

Related articles

AUG 21
$MRNAHighAI 8/10

Time High on 10.32% Session After Moderna Phase 3 Win

ARK Genomic Revolution ETF (ARKG) surged 10.32% to a record $47.67 after Moderna and Merck's mRNA cancer therapy succeeded in a Phase 3 trial. Moderna rose 177% to $174.38, Merck gained 13%. ARKG's top holdings, including Tempus AI (+23.91%), drove gains. The fund is up 64% YTD, 90% in 12 months.

tradingnews.com3 min
AUG 21
$MRKHighAI 8/10

Why Is Merck Stock Still An Undervalued Mega-Cap In Pharma?

Merck (MRK) stock surged 73% in the past year, outpacing the S&P 500, driven by successful clinical trials and FDA approvals. The company's pipeline, including LIPFENDRA and an mRNA cancer vaccine, addresses concerns about KEYTRUDA's patent expiration. Merck's forward P/E of 16x is lower than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY), suggesting potential undervaluation.

forbes.com2 min
AUG 21
$ROSTMed

Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more

BJ's Wholesale shares rose 4% after Q2 earnings beat estimates, with revenue at $6.09B and EPS guidance raised. Ross Stores also gained over 4% on strong Q2 results and upbeat Q3 guidance. Crypto-related stocks like Robinhood and Coinbase surged as bitcoin climbed over 20% for the week. Broadcom rose 1% on reports of a $60B debt plan for a deal. OSI Systems dropped 10% after missing revenue expectations. The Boston Beer Company fell 3% following CFO departure news. O-I Glass jumped 10% after a C

cnbc.com3 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 21
$MRKMedAI 8/10

Merck stock analysis: great pipeline at a stretched valuation

Merck (MRK) hit an all-time high of $153.53, up 78% in a year, after positive Phase 3 results for its mRNA cancer therapy with Moderna. Analysts are divided, with Goldman Sachs raising its target to $160 and UBS downgrading to Neutral at $150. Merck's revenue grew from $48.7B (2021) to $65.0B (2025), but it trades 7.5% above fair value with a high P/E of 55.2x. The stock is in overbought territory, with technical indicators suggesting potential exhaustion.

investing.com3 min